Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026. The filing also lists prior dispositions by Ms. Reed in the past three months: $278,317.00 for 10,000 shares on 02/17/2026, $96,360.09 for 2,994 shares on 02/04/2026, $230,463.88 for 7,175 shares on 02/03/2026, and $273,420.00 for 10,000 shares on 01/20/2026.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised stock options for 60,000 shares on February 20, 2026, converting an employee stock option into common stock at an exercise price of $15.4600 per share. He then sold 60,000 common shares in an open-market transaction at a weighted average price of $30.0961, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, his directly held common stock position was 432,886 shares.
TVTX filing: a Form 144 notice reports proposed sales of common shares by an affiliate and by Eric M. Dube. The filing lists an affiliate sale of 60,000 shares on 02/20/2026 (option originally granted 01/31/2020), and three recent sales by Eric M. Dube: 8,135, 51,865, and 100,087 shares on 01/23/2026, 01/27/2026, and 02/03/2026, respectively, with cash consideration shown.
Travere Therapeutics files its annual report describing a rare‑disease focused biopharma business built around FILSPARI and a growing pipeline. The company now has full FDA approval for FILSPARI to slow kidney function decline in adults with IgA nephropathy and is pursuing an additional indication in focal segmental glomerulosclerosis, with a supplemental application under FDA review and an April 13, 2026 PDUFA date.
Travere is also advancing pegtibatinase in a pivotal Phase 3 trial for classical homocystinuria after resolving manufacturing scale‑up issues and restarting enrollment in 2026. Existing revenue comes from rare kidney and metabolic products, including Thiola/Thiola EC, though these face generic competition. Globally, Travere relies on partners CSL Vifor and Chugai for FILSPARI commercialization outside the United States and highlights extensive patent and orphan‑drug exclusivity intended to protect key assets.
Travere Therapeutics, Inc. executive Elizabeth E. Reed, the Chief Legal Officer and General Counsel, reported option exercises and share sales in Travere stock. On February 17, 2026, she exercised an employee stock option for 10,000 shares, acquiring the same number of Travere common shares at a reported exercise price of $19.08 per share. The option, granted on January 4, 2017 and expiring on January 4, 2027, is fully vested and exercisable. On the same date, she sold 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262, in each case under a prearranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, she directly owns 105,211 shares of Travere common stock.
Travere Therapeutics reported strong growth for 2025 driven by its kidney drug FILSPARI. Fourth-quarter U.S. net product sales were $126.6 million, up from $73.5 million a year earlier, with FILSPARI contributing $103.3 million, a 108% increase. Full-year U.S. net product sales reached $410.5 million, compared with $226.7 million in 2024, including FILSPARI net product sales of $322.0 million, up 144%.
GAAP net income for Q4 2025 was $2.7 million, versus a loss of $60.3 million in Q4 2024, while full-year GAAP net loss narrowed to $25.5 million from $321.5 million. On a non-GAAP basis, the company reported Q4 net income of $33.3 million and full-year 2025 net income of $81.1 million.
Cash, cash equivalents and marketable securities totaled $322.8 million as of December 31, 2025, and Travere expects a $25 million sales-based milestone from Mirum in the first half of 2026. The FDA is reviewing a supplemental application for FILSPARI in FSGS with a PDUFA target action date of April 13, 2026. Enrollment has resumed in the Phase 3 HARMONY trial of pegtibatinase for classical homocystinuria.
Armistice Capital, LLC and Steven Boyd filed Amendment No. 8 to a Schedule 13G/A reporting beneficial ownership of 3,763,891 shares of Travere Therapeutics, Inc.
The filing states this equals 4.21% of the class and shows shared voting and shared dispositive power over 3,763,891 shares as of 12/31/2025. The filing is a joint reporting statement by Armistice Capital (investment manager to the Master Fund) and Steven Boyd, dated 02/17/2026.
Elizabeth Reed has filed a notice of intent to sell 10,000 shares of TVTX common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of February 17, 2026, and an aggregate market value of $278,317.
The 10,000 shares to be sold were acquired the same day through a stock option exercise from the issuer, paid in cash. Over the prior three months, Reed also sold TVTX common shares on several dates, generating gross proceeds ranging from $96,360.09 to $273,420.00 per transaction.
Perceptive Advisors LLC and affiliated entities report a significant minority stake in Travere Therapeutics, Inc. They beneficially own 4,278,180 shares of common stock, representing 4.8% of the company’s outstanding shares, based on 89,472,327 shares outstanding as of October 27, 2025.
The shares are directly held by Perceptive Life Sciences Master Fund, Ltd., with voting and investment power shared among the Master Fund, Perceptive Advisors, and Joseph Edelman. The group certifies the investment was not made to change or influence control of Travere Therapeutics.